FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
The innovaTV 301 study results fulfill the post-marketing requirement of the previous accelerated approval
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1585 results
NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in Patients with mUC
Frequent occurrence of NECTIN4 amplifications in other cancer types is promising for development of NECTIN4-targeted antibody drug conjugates in a tumour-agnostic context
Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and Triple-Negative Breast Cancers
Findings from the phase I TROPION-PanTumor01 study
EMA Recommends Extension of Indications for Amivantamab
New indication concerns combination therapy with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations
Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H Recurrent Endometrial or Ovarian Cancer
Genomic and tumour microenvironment parameters associated with response to PD1 blockade in dMMR cancers
FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or Refractory BRAF-Altered Paediatric Low-Grade Glioma
Evidence for efficacy is based on the results from the FIREFLY-1 study
Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-positive mBC with and without Brain Metastases
Findings from subgroup analyses of the DESTINY-Breast03 study
EMA Recommends Granting a Marketing Authorisation for Capivasertib
It is intended for the treatment of patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations
A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells Residing in Hydrothorax and Ascites from Patients with CUP
AI model TORCH achieved robust performance
FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Evidence for efficacy is based on the results from the QUILT-3.032 study
FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung Cancer
Evidence for efficacy is based on the results from the ALINA study
Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell Carcinoma Who Are At Increased Risk for Disease Recurrence After Nephrectomy
Findings from the KEYNOTE-564 study